Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: An analysis of a prospective trial
Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: An analysis of a prospective trial
R-CHOP with or without radiotherapy is the standard treatment for limited-stage diffuse large B-cell lymphoma (DLBCL). To prevent overtreatment, we assessed whether four cycles of CHOP plus six applications of rituximab was adequate with negative interim PET/CT and the role of consolidation radiotherapy specifically for patients with Waldeyer’s ring DLBCL.